Fox Run Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Fox Run Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,616	Closed	-$82K	–	1027
2018 Q1	$82K	Buy	+13,616	New	+$112K	0.02%	684

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Fox Run Management's INSY Position: Q2 2018 in Review

Fox Run Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2018, closing a stake of 13,616 shares — an estimated $82K sold.

Fox Run Management first reported a position in INSY in Q1 2018 and held it in 1 quarter. The position peaked at $82K in Q1 2018. 103 funds tracked by Wall St. Rank hold INSY as of Q2 2018.

Fox Run Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Fox Run Management sold 13,616 Insys Therapeutics, Inc. shares in Q2 2018, an estimated $82K.
Fox Run Management first reported a position in Insys Therapeutics, Inc. in Q1 2018 and held it in 1 quarter.
Fox Run Management's Insys Therapeutics, Inc. position peaked at $82K in Q1 2018.
103 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2018.

Based on Fox Run Management's 13F filing for Q2 2018, filed 17 Jul 2018.